Radar Therapeutics, a Berkeley, CA-based biotech company developing smart programmable medicines, raised $13.4M in Seed funding.
The round was led by NfX Bio. Major investors Eli Lilly and Company, Biovision Ventures, and KdT Ventures also joined with participation from PearVC, BEVC and other investors.
The company intends to use the funds for the advancement of its internal programs, team expansion and partnering.
Led by Sophia Lugo, CEO and Eerik Kaseniit, PhD, CSO and President, Radar is developing programmable genetic and mRNA-based therapeutics that use RNA sensors – mRNAs that gate their expression based on other RNAs in the cell – for specific payload expression to deliver targeted, timed delivery of the drug payload into the right cells at the right time. The RADAR platform enables “smart,” rationally designed precision therapeutics.
The company’s scientific advisory board includes Xiaojing Gao, PhD, Co-Founder, James J. Collins, PhD, Co-Founder, David Schaffer, PhD., Eric Klein, M.D., and Svetlana Lucas, PhD.
